• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

作者信息

Miao Yi, Sha Yeqin, Xia Yi, Qin Shuchao, Jiang Rui, Dai Luomengjia, Shen Hui, Qiu Tonglu, Wu Wei, Qiu Jingyan, Yang Yilian, Ding Chongyang, Wu Yujie, Fan Lei, Xu Wei, Li Jianyong, Zhu Huayuan

机构信息

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.

Pukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China.

出版信息

Blood Cancer J. 2023 Aug 9;13(1):121. doi: 10.1038/s41408-023-00890-y.

DOI:10.1038/s41408-023-00890-y
PMID:37558684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10412547/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32fc/10412547/f4bb3b82b4cf/41408_2023_890_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32fc/10412547/44b8c25d17a0/41408_2023_890_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32fc/10412547/f4bb3b82b4cf/41408_2023_890_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32fc/10412547/44b8c25d17a0/41408_2023_890_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32fc/10412547/f4bb3b82b4cf/41408_2023_890_Fig2_HTML.jpg

相似文献

1
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.伊布替尼联合氟达拉滨、环磷酰胺和利妥昔单抗（iFCR）作为伴有或不伴有TP53异常的慢性淋巴细胞白血病/小淋巴细胞白血病的初始治疗：一项中国队列的前瞻性真实世界研究
Blood Cancer J. 2023 Aug 9;13(1):121. doi: 10.1038/s41408-023-00890-y.
2
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.一线依鲁替尼与氟达拉滨、环磷酰胺和利妥昔单抗治疗慢性淋巴细胞白血病患者的疗效：一项回顾性多中心“真实世界”研究。
Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
3
Ibrutinib and rituximab for chronic lymphocytic leukaemia.依鲁替尼和利妥昔单抗治疗慢性淋巴细胞白血病
Lancet Oncol. 2019 Sep;20(9):e471. doi: 10.1016/S1470-2045(19)30528-5. Epub 2019 Aug 8.
4
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).慢性淋巴细胞白血病一线治疗进展：德国慢性淋巴细胞白血病研究小组（GCLLSG）关于管理和一线治疗的现行建议。
Eur J Haematol. 2016 Jan;96(1):9-18. doi: 10.1111/ejh.12678. Epub 2015 Nov 6.
5
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.在既往未接受治疗的慢性淋巴细胞白血病患者中进行的一项随机IIB期试验的临床疗效和成本效益结果，该试验比较氟达拉滨、环磷酰胺和利妥昔单抗与氟达拉滨、环磷酰胺、米托蒽醌和低剂量利妥昔单抗：慢性淋巴细胞白血病中减量化利妥昔单抗联合化疗（ARCTIC）试验。
Health Technol Assess. 2017 May;21(28):1-374. doi: 10.3310/hta21280.
6
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).在接受一线氟达拉滨、环磷酰胺和强化剂量奥法木单抗（FCO2）治疗的IGHV突变型慢性淋巴细胞白血病的年轻健康患者中，微小残留病缓解率很高。
Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.
7
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.美国商业保险覆盖的年轻慢性淋巴细胞白血病患者的真实世界治疗模式、不良事件、资源利用和成本：一项回顾性队列研究。
Adv Ther. 2020 Jul;37(7):3129-3148. doi: 10.1007/s12325-020-01350-w. Epub 2020 May 12.
8
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.慢性淋巴细胞白血病：2017 年诊断、风险分层和治疗更新。
Am J Hematol. 2017 Sep;92(9):946-965. doi: 10.1002/ajh.24826.
9
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.利妥昔单抗联合氟达拉滨和环磷酰胺或其他药物治疗慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132.
10
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.cenersen（一种 p53 反义抑制剂）联合氟达拉滨、环磷酰胺和利妥昔单抗治疗高危慢性淋巴细胞白血病的 II 期研究。
Leuk Lymphoma. 2012 Feb;53(2):218-24. doi: 10.3109/10428194.2011.610012. Epub 2011 Sep 23.

引用本文的文献

1
[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2025)].《中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊断与治疗指南（2025年版）》
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):105-112. doi: 10.3760/cma.j.cn121090-20241209-00551.

本文引用的文献

1
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.固定疗程伊布替尼联合维奈托克治疗初治 CLL： CAPTIVATE FD 队列的主要分析。
Blood. 2022 Jun 2;139(22):3278-3289. doi: 10.1182/blood.2021014488.
2
Frontline treatment in CLL: the case for time-limited treatment.CLL 的一线治疗：限时治疗的案例。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):59-67. doi: 10.1182/hematology.2021000233.
3
Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday.
限时联合治疗方案在慢性淋巴细胞白血病中的应用：实现药物假期的有前途策略。
Curr Med Sci. 2021 Jun;41(3):431-442. doi: 10.1007/s11596-021-2385-3. Epub 2021 Jun 28.
4
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.慢性淋巴细胞白血病的可测量残留病：专家综述与共识建议。
Leukemia. 2021 Nov;35(11):3059-3072. doi: 10.1038/s41375-021-01241-1. Epub 2021 Jun 24.
5
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.伊布替尼、氟达拉滨、环磷酰胺和奥滨尤珠单抗（iFCG）方案治疗伴有IGHV 突变且无 TP53 异常的慢性淋巴细胞白血病（CLL）。
Leukemia. 2021 Dec;35(12):3421-3429. doi: 10.1038/s41375-021-01280-8. Epub 2021 May 18.
6
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.奥妥珠单抗联合伊布替尼诱导治疗，随后采用微小残留病驱动策略治疗慢性淋巴细胞白血病患者（ICLL07 FILO）：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.
7
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.依鲁替尼联合氟达拉滨、环磷酰胺和利妥昔单抗作为年轻慢性淋巴细胞白血病患者的初始治疗：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.
8
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.伊布替尼作为慢性淋巴细胞白血病患者的初始治疗方法。
N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.